Galapagos Nv

Abbvie S.a.r.l.

Abbvie Overseas Sarl

Abbvie Global Enterprises Ltd.

Stephen N Greszler

Philip R Kym

Robert J Altenbach

Andrew Bogdan

Xueqing Wang

Ming Clinton Yeung

Bo Liu

Xenia Beebe Searle

Gregory A Gfesser

John R Koenig

Marlon D Cowart

Nicolas Desroy

Steven Emiel Van Der Plas

Marc J Scanio

Gang Zhao

Karine Fabienne Malagu

Eric A Voight

Hans Kelgtermans

Ghjuvanni Petru Diunisu Coti

Sachin V Patel

Christopher Gaëtan Housseman

Nuria Merayo Merayo

Mathieu Rafaël Pizzonero

Béranger Duthion

Sylvain Couty

Elsa De Lemos

William Ramesh Esmieu

Xeuquing Wang

The invention discloses compounds of Formula I, wherein X, X, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Heteroaryl substituted pyridines and methods of use

The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Substituted pyrrolidines and methods of use

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

The present invention provides for compounds of formula (I) wherein X, Y, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted tricyclics and method of use

The invention provides for compounds of formula (I) wherein R, X, Y, R, R, R, R, R, R, R, R, R, R, R, m, and R&#x2033; have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Substituted chromanes and method of use

Growing community of inventors

Vernon Hills, IL, United States of America

Stephen N Greszler